By efrat|2023-01-22T07:12:06+00:00January 22nd, 2023|All|Comments Off on Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
By efrat|2022-11-11T07:58:01+00:00November 11th, 2022|All|Comments Off on Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure
By efrat|2022-11-07T09:58:15+00:00November 7th, 2022|All|Comments Off on Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma
By efrat|2022-10-24T08:28:01+00:00October 24th, 2022|All|Comments Off on Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
By Amnon Ron|2022-10-17T08:48:06+00:00October 17th, 2022|All|Comments Off on Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL
By efrat|2022-10-06T14:41:38+00:00October 6th, 2022|All|Comments Off on Dr. Areej El-Jawahri – Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
By efrat|2022-09-21T08:19:47+00:00September 21st, 2022|All|Comments Off on Prof. He Huang – Non-viral, specifically targeted CAR-T cells, achieve high safety and efficacy in B-NHL
By efrat|2022-09-20T13:10:34+00:00September 20th, 2022|All|Comments Off on Prof. Mikkael Sekeres – Azacitidine plus venetoclax for myelodysplastic syndromes
